Non-viral gene delivery utilizing RALA modulates sFlt-1 secretion, important for preeclampsia

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia. Circ. Res. 124(7), 1094–1112 (2019).
  Medline CASGoogle Scholar
• 2. McNally R, Alqudah A, Obradovic D, McClements L. Elucidating the pathogenesis of pre-eclampsia using in vitro models of spiral uterine artery remodeling. Curr. Hypertens. Rep. 19(11), 93 (2017).
  MedlineGoogle Scholar
• 3. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 30(Suppl. A), S32–S37 (2009).
  MedlineGoogle Scholar
• 4. Aneman I, Pienaar D, Suvakov S, Simic TP, Garovic VD, McClements L. Mechanisms of key innate immune cells in early- and late-onset preeclampsia. Front. Immunol. 11 (2020). • This review provides a comprehensive outline of distinct and overlapping mechanisms regulating different phenotypes of preeclampsia contributing to the body of knowledge and a better understanding of preeclampsia.
  MedlineGoogle Scholar
• 5. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. 90(22), 10705–10709 (1993).
  Medline CASGoogle Scholar
• 6. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111(5), 649–658 (2003). •• This is one of the first studies that demonstrated the importance of sFlt-1 in inducing preeclampsia symptoms and features in vivo.
  Medline CASGoogle Scholar
• 7. Yu Y, Jenkins AJ, Nankervis AJ et al. Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia 52(1), 160–168 (2009).
  Medline CASGoogle Scholar
• 8. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7), 672–683 (2004).
  Medline CASGoogle Scholar
• 9. Zeisler H, Llurba E, Chantraine F et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 374(1), 13–22 (2016).
  Medline CASGoogle Scholar
• 10. Thadhani R, Hagmann H, Schaarschmidt W et al. Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27(3), 903–913 (2016).
  Medline CASGoogle Scholar
• 11. Sela S, Itin A, Natanson-Yaron S et al. A Novel human-specific soluble vascular endothelial growth factor receptor 1. Circ. Res. 102(12), 1566–1574 (2008).
  Medline CASGoogle Scholar
• 12. Thomas CP, Andrews JI, Raikwar NS et al. A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. J. Clin. Endocrinol. Metab. 94(7), 2524–2530 (2009). •• Here, a specific variant of sFlt-1 (e15a) was identified as the main isoform enriched in placentae with potential application for preeclampsia development.
  Medline CASGoogle Scholar
• 13. Kar M. Role of biomarkers in early detection of preeclampsia. J. Clin. Diagnostic Res. 8(4), BE01 (2014).
  MedlineGoogle Scholar
• 14. Valentine A, O'Rourke M, Yakkundi A et al. FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin. Cancer Res. (2011).
  MedlineGoogle Scholar
• 15. Yakkundi A, Bennett R, Hernández-Negrete I et al. FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis. Arterioscler. Thromb. Vasc. Biol. 35(4), 845–854 (2015). •• This is the first report that demonstrates the importance of FKBPL in developmental and physiological angiogenesis and the development of Fkbpl haploinsufficient mouse model.
  Medline CASGoogle Scholar
• 16. Robson T, James IF. The therapeutic and diagnostic potential of FKBPL; A novel anticancer protein. Drug Discov. Today 11-12, 544–8 (2012).
  Google Scholar
• 17. Chang CW, Wakeland AK, Parast MM. Trophoblast lineage specification, differentiation and their regulation by oxygen tension. J. Endocrinol. 236(1), R43–R56 (2018).
  Medline CASGoogle Scholar
• 18. Ji L, Brkić J, Liu M, Fu G, Peng C, Wang YL. Placental trophoblast cell differentiation: physiological regulation and pathological relevance to preeclampsia. Mol. Aspects Med. 34(5), 981–1023 (2013).
  Medline CASGoogle Scholar
• 19. McClements L, Yakkundi A, Papaspyropoulos A et al. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin. Cancer Res. 19(14), 3881–3893 (2013).
  Medline CASGoogle Scholar
• 20. McClements L, Annett S, Yakkundi A et al. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer. 19(1), 351 (2019).
  MedlineGoogle Scholar
• 21. Todd N, McNally R, Alqudah A et al. Role of A Novel angiogenesis FKBPL-CD44 pathway in preeclampsia risk stratification and mesenchymal stem cell treatment. J. Clin. Endocrinol. Metab. 106(1), 26–41 (2021). •• This is the first report to demonstrate the predictive and diagnostic biomarker potential of FKBPL and its target protein, CD44, in preeclampsia. FKBPL's role as a target of potential treatment for preeclampsia based on mesenchymal stem cells was also described.
  MedlineGoogle Scholar
• 22. Januszewski AS, Watson CJ, O'Neill V et al. FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. Sci. Rep. 10(1), 21655 (2020).
  Medline CASGoogle Scholar
• 23. Lui NA, Jeyaram G, Henry A. Postpartum interventions to reduce long-term cardiovascular disease risk in women after hypertensive disorders of pregnancy: a systematic review. Front. Cardiovasc. Med. 6, 160 (2019).
  MedlineGoogle Scholar
• 24. Liu Chung Ming C, Sesperez K, Ben-Sefer E et al. Considerations to model heart disease in women with preeclampsia and cardiovascular disease. Cells. 10(4), 899 (2021). •• This comprehensive review critically evaluates current preclinical models of preeclampsia and discusses the need for more reliable and personalized models of this disease. It particularly emphasizes the need for preclinical models that recapitulate future cardiovascular disease and endothelial dysfunction as a result of preeclampsia in pregnancy.
  MedlineGoogle Scholar
• 25. Marshall SA, Hannan NJ, Jelinic M, Nguyen TPH, Girling JE, Parry LJ. Animal models of preeclampsia: translational failings and why. Am. J. Physiol. Integr. Comp. Physiol. 314(4), R499–R508 (2018).
  Medline CASGoogle Scholar
• 26. Riley MK, Vermerris W. Recent advances in nanomaterials for gene delivery – a review. Nanomaterials 7(5), 94 (2017).
  MedlineGoogle Scholar
• 27. Roth TL, Puig-Saus C, Yu R et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559(7714), 405–409 (2018).
  Medline CASGoogle Scholar
• 28. McCarthy HO, McCaffrey J, McCrudden CM et al. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. J. Control. Release 189, 141–149 (2014). •• This is the first report of a novel nonviral gene-delivery system, RALA, that fully characterizes its potential for safe and effective gene delivery in vitro and in vivo.
  Medline CASGoogle Scholar
• 29. Mulholland EJ, Ali A, Robson T, Dunne NJ, McCarthy HO. Delivery of RALA/siFKBPL nanoparticles via electrospun bilayer nanofibres: an innovative angiogenic therapy for wound repair. J. Control. Release. 316, 53–65 (2019).
  Medline CASGoogle Scholar
• 30. Raikwar NS, Liu KZ, Thomas CP. Protein kinase C regulates FLT1 abundance and stimulates its cleavage in vascular endothelial cells with the release of a soluble PlGF/VEGF antagonist. Exp. Cell Res. 319(17), 2578–2587 (2013).
  Medline CASGoogle Scholar
• 31. Bennett R, Yakkundi A, McKeen HD et al. RALA-mediated delivery of FKBPL nucleic acid therapeutics. Nanomedicine (Lond). 10(19), 2989–3001 (2015). • RALA is efficient at delivering FKBPL as a therapeutic in vivo to treat cancer. This study validated RALA's potential for safe and effective delivery of nucleic acid therapeutics.
  CASGoogle Scholar
• 32. Lu F, Longo M, Tamayo E et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstet. Gynecol. 196(4), 396.e1–396.e7 (2007).
  MedlineGoogle Scholar
• 33. Szalai G, Romero R, Chaiworapongsa T et al. Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS ONE 10(4), e0119547 (2015).
  MedlineGoogle Scholar
• 34. McCrudden CM, McBride JW, McCaffrey J et al. Systemic RALA/iNOS nanoparticles: a potent gene therapy for metastatic breast cancer coupled as a biomarker of treatment. Mol. Ther. Nucleic Acids 6, 249–258 (2017).
  Medline CASGoogle Scholar
• 35. McCrudden CM, McBride JW, McCaffrey J et al. Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer. Cancer Nanotechnol. 9(1), 5 (2018).
  MedlineGoogle Scholar
• 36. Dong X, Gou W, Li C et al. Proteinuria in preeclampsia: not essential to diagnosis but related to disease severity and fetal outcomes. Pregnancy Hypertens. 8, 60–64 (2017).
  MedlineGoogle Scholar
• 37. Podjarny E, Losonczy G, Baylis C. Animal models of preeclampsia. Semin. Nephrol. 24(6), 596–606 (2004).
  MedlineGoogle Scholar
• 38. Sunderland N, Hennessy A, Makris A. Animal models of pre-eclampsia. Am. J. Reprod. Immunol. 65(6), 533–541 (2011).
  Medline CASGoogle Scholar
• 39. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56(4), 549–580 (2004).
  Medline CASGoogle Scholar
• 40. Karumanchi SA, Stillman IE. In vivo rat model of preeclampsia. Methods Mol. Med. 122, 393–399 (2006).
  MedlineGoogle Scholar
• 41. Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12(6), 642–649 (2006).
  Medline CASGoogle Scholar
• 42. Kumasawa K, Ikawa M, Kidoya H et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc. Natl Acad. Sci. U. S. A. 108(4), 1451–1455 (2011).
  Medline CASGoogle Scholar
• 43. Bergmann A, Ahmad S, Cudmore M et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J. Cell. Mol. Med. 14(6B), 1857–1867 (2010).
  Medline CASGoogle Scholar
• 44. Martinez-Fierro ML, Hernández-Delgadillo GP, Flores-Morales V et al. Current model systems for the study of preeclampsia. Exp. Biol. Med. (Maywood). 243(6), 576–585 (2018).
  Medline CASGoogle Scholar
• 45. Young LS, Mautner V. The promise and potential hazards of adenovirus gene therapy. Gut 48(5), 733–736 (2001).
  Medline CASGoogle Scholar
• 46. Cole G, Ali AA, McCrudden CM et al. DNA vaccination for cervical cancer: strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system. Eur. J. Pharm. Biopharm. 127, 288–297 (2018).
  Medline CASGoogle Scholar
• 47. Turanov AA, Lo A, Hassler MR et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36(12), 1164–1173 (2018).
  CASGoogle Scholar